Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions

Bibliography

• MDPoe, SLChagnon, MLEscolar. Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol 2014;76:747-53
   PubMed Web of Science ®Google Scholar
• FJStoop, MCKruyt, MHvan der Linden, et al. Prevalence and development of orthopaedic symptoms in the Dutch Hurler patient population after haematopoietic stem cell transplantation. JIMD Rep 2013;9:17-29
   PubMedGoogle Scholar
• EJLangereis, ABorgo, ECrushell, et al. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 2013;8:155
   PubMedGoogle Scholar
• JJBoelens, VKPrasad, JTolar, et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 2010;57:123-45
   PubMed Web of Science ®Google Scholar
• ATanaka, TOkuyama, YSuzuki, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 2012;107:513-20
   PubMed Web of Science ®Google Scholar
• LWelling, JPMarchal, Pvan Hasselt, et al. Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III. JIMD Rep 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• RGiugliani, SHerber, LLapagesse, et al. Therapy for mucopolysaccharidosis VI: (Maroteaux-Lamy syndrome) present status and prospects. Pediatr Endocrinol Rev 2014;12(Suppl 1):152-8
   PubMedGoogle Scholar
• TBraulke, JSBonifacino. Sorting of lysosomal proteins. Biochim Biophys Acta 2009;1793:605-14
   PubMed Web of Science ®Google Scholar
• SOrtolano, IVieitez, CNavarro, et al. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov 2014;8:9-25
   PubMedGoogle Scholar
• MBalwani, CBreen, GMEnns, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013;58:950-7
   PubMed Web of Science ®Google Scholar
• EDKakkis, MFMcEntee, ASchmidtchen, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996;58:156-67
   PubMedGoogle Scholar
• JMuenzer, JCLamsa, AGarcia, et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002;91:98-9
   PubMedGoogle Scholar
• MDvorak-Ewell, DWendt, CHague, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One 2010;5:e12194
   PubMed Web of Science ®Google Scholar
• ACCrawley, DABrooks, VJMuller, et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest 1996;97:1864-73
   PubMed Web of Science ®Google Scholar
• EDKakkis, ESchuchman, XHe, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001;72:199-208
   PubMed Web of Science ®Google Scholar
• EDKakkis, JMuenzer, GETiller, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8
   PubMed Web of Science ®Google Scholar
• JEWraith, LAClarke, MBeck, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144:581-8
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17
   PubMed Web of Science ®Google Scholar
• JMuenzer, JEWraith, MBeck, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73
   PubMed Web of Science ®Google Scholar
• PHarmatz, RGiugliani, ISchwartz, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9
   PubMed Web of Science ®Google Scholar
• CJHendriksz, BBurton, TRFleming, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis 2014;37:979-90
   PubMed Web of Science ®Google Scholar
• JEFox, LVolpe, JBullaro, et al. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab 2015;114:203-8
   PubMed Web of Science ®Google Scholar
• A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02230566?term=Mucopolysaccharidosis+VII&rank=2 [Cited 26 January 2015]
   Google Scholar
• LAClarke, JEWraith, MBeck, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123:229-40
   PubMed Web of Science ®Google Scholar
• CLampe, AKBosserhoff, BKBurton, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis 2014;37:823-9
   PubMed Web of Science ®Google Scholar
• CJHendriksz, RGiugliani, PHarmatz, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 2013;36:373-84
   PubMed Web of Science ®Google Scholar
• JMuenzer. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 2014;111:63-72
   PubMed Web of Science ®Google Scholar
• WLHwu, YHChien, NCLee, et al. Application of mass spectrometry in newborn screening: about both small molecular diseases and lysosomal storage diseases. Top Curr Chem 2014;336:177-96
   PubMedGoogle Scholar
• ATAnbu, JMercer, JEWraith. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis 2006;29:230-1
   PubMedGoogle Scholar
• AJurecka, ZZuberuber, VOpoka-Winiarska, et al. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 2012;107:508-12
   PubMedGoogle Scholar
• AJurecka, VMalinova, ATylki-Szymanska. Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases. Mol Genet Metab 2014;111:212-13
   PubMedGoogle Scholar
• GWegrzyn, AWegrzyn, ATylki-Szymanska. A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypotheses 2004;62:986-92
   PubMedGoogle Scholar
• EMiebach. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther 2009;47(Suppl 1):S100-6
   Google Scholar
• EJLangereis, Nvan Vlies, HJChurch, et al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab 2015;114:129-37
   PubMed Web of Science ®Google Scholar
• AJBarbier, BBielefeld, DAWhiteman, et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab 2013;110:303-10
   PubMed Web of Science ®Google Scholar
• JKim, MRPark, DSKim, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy 2013;68:796-802
   PubMed Web of Science ®Google Scholar
• SKasugai, RFujisawa, YWaki, et al. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 2000;15:936-43
   PubMed Web of Science ®Google Scholar
• STomatsu, AMMontano, VCDung, et al. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther 2010;18:1094-102
   PubMed Web of Science ®Google Scholar
• PDickson, MMcEntee, CVogler, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007;91:61-8
   PubMed Web of Science ®Google Scholar
• MVMunoz-Rojas, TVieira, RCosta, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008;146A:2538-44
   PubMed Web of Science ®Google Scholar
• MVMunoz-Rojas, DDHorovitz, LBJardim, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 2010;99:346-50
   PubMed Web of Science ®Google Scholar
• JMuenzer, CHendriksz, MBStein, et al. Investigational intrathecal enzyme replacement therapy for children with severe form of Hunter syndrome. (Mucopolysaccharidosis II): (Abstract, presented at the 13th International MPS Symposium, Sauipe, Bahia, Brazil, August 13-17, 2014). J Inborn Errors Metab Screening 2014;2:67
   Google Scholar
• RJBoado, YZhang, YZhang, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 2008;99:475-84
   PubMed Web of Science ®Google Scholar
• RJBoado, EKHui, JZLu, et al. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm 2011;8:1342-50
   PubMed Web of Science ®Google Scholar
• RJBoado, EKa-Wai Hui, JZhiqiang Lu, et al. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng 2014;111:2317-25
   PubMed Web of Science ®Google Scholar
• RJBoado, JZLu, EKHui, et al. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol Pharm 2014;11:2928-34
   PubMed Web of Science ®Google Scholar
• CMSimonaro, YGe, EEliyahu, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010;107:222-7
   PubMed Web of Science ®Google Scholar
• EEliyahu, TWolfson, YGe, et al. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One 2011;6:e22447
   PubMed Web of Science ®Google Scholar
• MSSands, BLDavidson. Gene therapy for lysosomal storage diseases. Mol Ther 2006;13:839-49
   PubMed Web of Science ®Google Scholar
• RLMango, LXu, MSSands, et al. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 2004;82:4-19
   PubMed Web of Science ®Google Scholar
• ARuzo, MGarcia, ARibera, et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther 2012;20:254-66
   PubMed Web of Science ®Google Scholar
• CHinderer, PBell, BLGurda, et al. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proc Natl Acad Sci USA 2014;111:14894-9
   PubMed Web of Science ®Google Scholar
• CHinderer, PBell, BLGurda, et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 2014;22:2018-27
   PubMed Web of Science ®Google Scholar
• CCiron, NDesmaris, MAColle, et al. Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 2006;60:204-13
   PubMed Web of Science ®Google Scholar
• AIBrooks, CSStein, SMHughes, et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002;99:6216-21
   PubMed Web of Science ®Google Scholar
• HFu, JDiRosario, LKang, et al. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med 2010;12:624-33
   PubMed Web of Science ®Google Scholar
• VHaurigot, SMarco, ARibera, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013;123:3254
   PubMed Web of Science ®Google Scholar
• MSardiello, IAnnunziata, GRoma, et al. Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. Hum Mol Genet 2005;14:3203-17
   PubMed Web of Science ®Google Scholar
• MTardieu, MZerah, BHusson, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 2014;25:506-16
   PubMed Web of Science ®Google Scholar
• IVisigalli, SDelai, LSPoliti, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010;116:5130-9
   PubMed Web of Science ®Google Scholar
• ALangford-Smith, FLWilkinson, KJLangford-Smith, et al. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther 2012;20:1610-21
   PubMed Web of Science ®Google Scholar
• KOhmi, DSGreenberg, KSRajavel, et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003;100:1902-7
   PubMed Web of Science ®Google Scholar
• ASergijenko, ALangford-Smith, AYLiao, et al. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 2013;21:1938-49
   PubMed Web of Science ®Google Scholar
• ABiffi, EMontini, LLorioli, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158
   PubMed Web of Science ®Google Scholar
• DABrooks, VJMuller, JJHopwood. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12:367-73
   PubMed Web of Science ®Google Scholar
• LKHein, MBawden, VJMuller, et al. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004;338:453-62
   PubMed Web of Science ®Google Scholar
• EMWelch, ERBarton, JZhuo, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
   PubMed Web of Science ®Google Scholar
• SHirawat, EMWelch, GLElfring, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-44
   PubMed Web of Science ®Google Scholar
• SWPeltz, MMorsy, EMWelch, et al. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 2013;64:407-25
   PubMed Web of Science ®Google Scholar
• RBartolomeo, EVPolishchuk, NVolpi, et al. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 2013;36:363-71
   PubMed Web of Science ®Google Scholar
• DJMc Carthy, MMalhotra, AMO’Mahony, et al. Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance. Pharm Res 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• FQMayer, MDAdorne, EABender, et al. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res 2015;32:941-54
   PubMed Web of Science ®Google Scholar
• HVinazzer. Antithrombotic therapy in patients with known risk factors for thromboembolism. Folia Haematol Int Mag Klin Morphol Blutforsch 1989;116:927-34
   PubMedGoogle Scholar
• EHSchuchman, YGe, ALai, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 2013;8:e54459
   PubMed Web of Science ®Google Scholar
• MFrohbergh, YGe, FMeng, et al. Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. PLoS One 2014;9:e100882
   PubMed Web of Science ®Google Scholar
• NJWeinreb. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 2013;11(Suppl 1):77-90
   PubMedGoogle Scholar
• EPiotrowska, JJakobkiewicz-Banecka, SBaranska, et al. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006;14:846-52
   PubMed Web of Science ®Google Scholar
• AArfi, MRichard, CGandolphe, et al. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 2010;33:61-7
   PubMed Web of Science ®Google Scholar
• TOtomo, MAHossain, KOzono, et al. Genistein reduces heparan sulfate accumulation in human mucolipidosis II skin fibroblasts. Mol Genet Metab 2012;105:266-9
   PubMed Web of Science ®Google Scholar
• AFriso, RTomanin, MSalvalaio, et al. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159:1082-91
   PubMed Web of Science ®Google Scholar
• MMalinowska, FLWilkinson, KJLangford-Smith, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010;5:e14192
   PubMed Web of Science ®Google Scholar
• MMoskot, SMontefusco, JJakobkiewicz-Banecka, et al. The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. J Biol Chem 2014;289:17054-69
   PubMed Web of Science ®Google Scholar
• EPiotrowska, JJakóbkiewicz-Banecka, ATylki-Szymanska, et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 2008;69:166-79
   PubMed Web of Science ®Google Scholar
• Jde Ruijter, MJValstar, MNarajczyk, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012;71:110-20
   PubMed Web of Science ®Google Scholar
• RMMcClain, EWolz, ADavidovich, et al. Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol 2005;43:1461-82
   PubMed Web of Science ®Google Scholar
• KHKim, CDodsworth, AParas, et al. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab 2013;109:382-5
   PubMed Web of Science ®Google Scholar
• SDKingma, TWagemans, LIJlst, et al. Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models. J Inherit Metab Dis 2014;37:813-21
   PubMedGoogle Scholar
• JQFan. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003;24:355-60
   PubMed Web of Science ®Google Scholar
• GParenti, MMoracci, SFecarotta, et al. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem 2014;6:1031-45
   PubMed Web of Science ®Google Scholar
• MFeldhammer, SDurand, LMrazova, et al. Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene. Hum Mutat 2009;30:918-25
   PubMed Web of Science ®Google Scholar
• MFeldhammer, SDurand, AVPshezhetsky. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One 2009;4:e7434
   PubMed Web of Science ®Google Scholar
• PFBoudes. Gene therapy as a new treatment option for inherited monogenic diseases. Eur J Intern Med 2014;25:31-6
   PubMedGoogle Scholar
• CEHollak, FAWijburg. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 2014;37:587-98
   PubMed Web of Science ®Google Scholar